Assessing Cellebrite DI (CLBT) Valuation After Its Spring 2026 Digital Forensics Release

Cellebrite DI (NasdaqGS:CLBT) is back in focus after its Spring 2026 Release, which broadens device access across iOS and Android, adds Google Cloud based Corellium, Safeguard Mode, drone forensics, and tools for automotive systems testing.

See our latest analysis for Cellebrite DI.

Despite the product launch, the recent share price performance has been weak, with a 1 day share price return of an 11.12% decline and a year to date share price return of a 38.17% decline, while the 3 year total shareholder return of 92.16% points to stronger longer term momentum.

If Cellebrite’s latest release has you thinking more broadly about digital forensics and AI, it could be worth scanning 69 profitable AI stocks that aren't just burning cash

With the share price under pressure and Cellebrite reporting US$475.675m in revenue and US$77.813m in net income, plus an intrinsic discount of 32.90%, the key question is whether this represents a buying opportunity or if markets are already pricing in future growth.

Most Popular Narrative: 49.1% Undervalued

With Cellebrite DI last closing at $11.03 against a most followed fair value of $21.67, the current price sits well below that narrative estimate.

The continued transition to a recurring, subscription-based revenue model with over 90% of revenues now from subscriptions and growing SaaS and cloud penetration improves revenue visibility, predictability, and operating leverage, which is already translating into higher EBITDA and free cash flow margins and is likely underappreciated in current valuations.

Read the complete narrative.

Want to see what is sitting behind that confidence in subscriptions, margins, and cash flows? The valuation hinges on stretching these strengths much further than today.

Result: Fair Value of $21.67 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this hinges on continued execution, as heavier R&D needs to keep pace with Apple and Google security, and reliance on US federal contracts could undermine those assumptions.

Find out about the key risks to this Cellebrite DI narrative.

Another View: Multiples Point to a Richer Price Tag

So far, the story leans on fair value estimates that suggest Cellebrite DI looks cheap. The P/E picture tells something different. At 35.4x earnings, the company trades above the US Software industry on 27.8x and above its own fair ratio of 28.1x, which means less margin for error if growth or execution wobbles.

When a stock screens expensive relative to both peers at 41.4x on average and an internal fair ratio the market could move towards, it raises a practical question for you: are you comfortable paying up today for this growth profile, or would you want a wider buffer?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mix of optimism and caution in this story leaves you unsure, take a closer look at the numbers yourself, move quickly to shape your own view, then check the 4 key rewards

Looking for more investment ideas?

If Cellebrite has sharpened your interest, do not stop here, broaden your watchlist with other ideas that match your style before the market moves on.

• Target dependable cash generators by reviewing companies in the screener containing 23 high quality undiscovered gems that may not be on everyone’s radar yet.
• Prioritise resilience by checking out the 72 resilient stocks with low risk scores and see which businesses score well on stability.
• Strengthen your long term core holdings by scanning the solid balance sheet and fundamentals stocks screener (41 results) for companies with healthier finances.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com